%0 Journal Article
%T Patient engagement in first cycle comprehensive chemotherapy consultation pharmacist services and impact on patient activation
%A Benyam Muluneh
%A Jacqueline E McLaughlin
%A Jessica Auten
%A Jill S Bates
%A Katherine P Morgan
%A Lindsey Amerine
%A Margaret R Sketch
%A Matthew C Foster
%A Nicole R Pinelli
%A Stephen Michael Clark
%A Tejendra Patel
%J Journal of Oncology Pharmacy Practice
%@ 1477-092X
%D 2019
%R 10.1177/1078155219832644
%X Healthcare systems and policy makers worldwide are demonstrating interest in shared decision making, which requires patient activation. Patient activation can be measured using a validated tool called the patient activation measure-10. First cycle comprehensive chemotherapy consultation services (3CS) is provided by an oncology pharmacy team member during a patient encounter at the beginning of the patient's treatment for cancer. This was a single center, prospective, non-randomized, observational clinical study in patients with cancer who required a new chemotherapy plan. A baseline patient activation measure-10 survey was administered and a pharmacy team member met with the patient to complete the first cycle 3CS encounter. Within two business days of that encounter, a second patient activation measure-10 survey was administered, and thus, patients served as their own control. Forty-nine patients who met the inclusion criteria were enrolled, of which 36 completed the study. Mean patient activation measure-10 scores measured at baseline and two business days after the 3CS encounter were significantly different (68.5£¿¡À£¿SD 14.7 vs. 75.0£¿¡À£¿SD 14.3, p£¿=£¿0.001). This difference persisted when evaluated by gender (female: 70.0£¿¡À£¿SD 14.8 vs. 81.6£¿¡À£¿SD 10.5, p£¿=£¿0.001; male: 66.1£¿¡À£¿SD 14.8 vs. 70.8£¿¡À£¿SD 14.7, p£¿=£¿0.022). This study demonstrates that cancer patients had significantly increased patient activation scores after engagement in a 3CS encounter provided by an oncology pharmacy team. Further studies are needed to verify these data in a larger population, different healthcare settings, and to evaluate for patients who have solid tumor malignancies
%K Chemotherapy
%K patient activation
%K patient education
%K patient engagement
%K pharmacist
%U https://journals.sagepub.com/doi/full/10.1177/1078155219832644